Kamada (NASDAQ:KMDA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kamada (NASDAQ:KMDA) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the biotechnology company’s stock.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $7.41 on Friday. Kamada has a 1-year low of $4.74 and a 1-year high of $8.00. The business has a fifty day moving average price of $6.06 and a 200 day moving average price of $5.67. The stock has a market capitalization of $425.93 million, a P/E ratio of 26.46 and a beta of 0.98.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kamada stock. Plato Investment Management Ltd bought a new stake in Kamada Ltd. (NASDAQ:KMDA) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.